For Providers: COVID-19 and MIS-C Testing at Children’s Hospital & Medical Center

Children’s Hospital & Medical Center’s goal is to provide the highest level of care for the community’s children, as well as support the primary care providers who care for them. We want to share with you information on our process for testing pediatric patients for COVID-19 and information on screening for Multisystem Inflammatory Syndrome in Children (MIS-C).

COVID-19 Testing Process

If you are affiliated with a health system with a lab that is processing COVID-19 testing, please have your patient tested through your affiliated system.

If you are not affiliated with a health system with a lab that is processing COVID-19 testing, and you have a patient that needs to be tested, please follow the steps below:

  1. Have the legal guardian call Children’s Access Center at 402-955-4066 to complete the registration process and let them know the child is coming to the Respiratory Assessment Center (RAC) with a prescription.
  2. Send a paper prescription with the patient.
  3. The RAC is located on the east side of Children’s, and can be accessed from 84th Street between West Dodge Road and Indian Hills Drive. Families should turn into the entrance by the large white tent and follow the directional signage. They will then be greeted and screened by Children’s staff. Please note: The patient should be accompanied by an adult who has NOT tested positive for COVID-19.

If you have a symptomatic patient who has not been physically seen by you, please follow these steps:

  1. Direct the parent to call Children’s COVID-19 Hotline at 402-955-3200.
  2. A virtual visit will be scheduled. If it’s deemed appropriate, the patient will be sent to the RAC for a physical assessment and test. All documentation and test results will be available for your review via Physician Connect.

Please note: You will be responsible for contacting your patient families with results and reviewing self-isolation guidance based on test results.

Monoclonal Antibody Therapy Available for Some COVID-19 Patients

Effective Dec. 2, Children’s will begin offering bamlanivimab, a monoclonal antibody drug, to non-hospitalized patients who meet certain guidelines. It is authorized for use by the FDA under Emergency Use Authorization (EUA), and is intended to bind the SARS-CoV-2 virus to prevent further viral replication and stop further progression of the disease. The medication, approved for children age 12 and over, is administered via infusion. Because the supply is scarce, the medication will be offered only to patients who:

  • Weigh more than 88 pounds
  • Test positive for COVID-19 (PCR or Antigen)
  • Have mild to moderate illness (not hospitalized)
  • Have certain high-risk conditions as defined in the EUA (such as diabetes, obesity, sickle cell disease, congenital heart disease, immunosuppressive therapy, etc.)

Screening for Multisystem Inflammatory Syndrome in Children

Although MIS-C is a rare occurrence, quick diagnosis is important in expediting positive outcomes. Children’s hospitalist team has developed a MIS-C screening algorithm.


Disclaimer: Pathways and/or protocols are intended as a guide for practitioners and do not indicate an exclusive course of treatment nor serve as a standard of medical care. These pathways and/or protocols should be adapted by medical providers, when indicated, based on their professional judgment and taking into account individual patient and family circumstances.

Download PDF of MIS-C screening algorithm.

Please review these guidelines and if you have any non-emergent questions, contact Dr. Aleisha Nabower at

For an immediate consult, please call Children’s Physicians Priority Line at 855-850-5437.

Acute COVID-19 Infection VS Multisystem Inflammatory Syndrome in Children (MIS-C)

COVID-19 and MIS-C Educational Videos



Search the Children's Omaha Website

Looking for a provider?